Abbott Laboratories
Abbott Laboratories (ABT) Covered Calls
As of September 25, 2026, ABT has 187 covered call opportunities in the coming three months. Return ranges from 1.6 to 97.7% until expiration. Annualized return ranges from 8.7 to 251.2%. The nearest expiration is October 2, 2026. Maximum potential profit is $9,891.
Read more
Running ABT covered calls helps you generate consistent income from Abbott Laboratories's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Abbott Laboratories involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ABT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ABT stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABT covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Abbott Laboratories covered call is worth writing.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Income-focused investors, long-term ABT holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ABT covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Abbott Laboratories covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV percentile95.24% Elevated
- Market cap (M$)175,271
- 52 weeks high-25.22%
- 52 weeks low23.57%
- Analyst recommendationBuy
1.60 - Target price$120.75
19.46% above the current stock price - Dividend—
- Payout ratio64.54%
- Earnings date2026-10-21
- P/E32.74
- Future P/E16.70
- EPS (ttm)3.09
- EPS growth next 5 years9.30%
As of September 25, 2026
| 2026-10-09 | 14 | 111.00 | 9.59 | 0.05 | 2.20 | 976.00 | 9.64 | 251.22 | -0.05 | +0.20 | 31 | 2.15 |
| 2026-10-02 | 7 | 106.00 | 4.65 | 0.05 | 0.20 | 476.00 | 4.70 | 245.04 | -0.05 | +0.08 | 41 | 0.15 |
| 2026-10-16 | 21 | 115.00 | 13.54 | 0.05 | 0.10 | 1376.00 | 13.58 | 236.12 | -0.05 | +0.03 | 2,164 | 0.05 |
| 2026-11-20 | 56 | 135.00 | 33.28 | 0.05 | 0.20 | 3376.00 | 33.33 | 217.24 | -0.05 | +0.02 | 199 | 0.15 |
| 2026-10-09 | 14 | 109.00 | 7.61 | 0.05 | 0.80 | 776.00 | 7.66 | 199.74 | -0.05 | +0.13 | 56 | 0.75 |
| 2026-10-02 | 7 | 105.00 | 3.66 | 0.15 | 0.45 | 386.00 | 3.81 | 198.71 | -0.15 | +0.16 | 92 | 0.30 |
| 2026-10-16 | 21 | 111.00 | 9.59 | 0.15 | 0.30 | 986.00 | 9.73 | 169.19 | -0.15 | +0.08 | 0 | 0.15 |
| 2026-10-30 | 35 | 117.00 | 15.51 | 0.10 | 0.45 | 1581.00 | 15.61 | 162.78 | -0.10 | +0.07 | 1 | 0.35 |
| 2026-10-02 | 7 | 104.00 | 2.68 | 0.35 | 1.45 | 306.00 | 3.02 | 157.53 | -0.35 | +0.30 | 88 | 1.10 |
| 2026-11-20 | 56 | 125.00 | 23.41 | 0.10 | 0.30 | 2381.00 | 23.51 | 153.21 | -0.10 | +0.04 | 6,071 | 0.20 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best ABT covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→